相关实验视频

Updated: Jan 11, 2026

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

选择性HDAC6抑制剂WT161通过抑制急性淋巴细胞白血病中的PKA活性来调节VLA-4/FAK通路

Chengfang Lv¹, Yingling Zhao¹, Ling Luo¹

¹Department of Hematology, Shenzhen Longgang Central Hospital, Shenzhen, 518100, China.

Scientific reports

|November 17, 2025

概括

选择性HDAC6抑制剂WT161通过向VLA-4/FAK通路,显示出治疗急性淋巴细胞白血病 (ALL) 的前景. 这种表观遗传药物减少了癌细胞的生长,粘附和迁移,同时提高了化疗的有效性.

科学领域:

在瘤学瘤学.
表观遗传学在表观遗传学中,表观遗传学是指表观遗传学.
分子生物学分子生物学

背景情况:

急性淋巴细胞白血病 (ALL) 是一种复杂的癌症,由于药物耐药性和复发,预后不佳.
基因组脱乙酶6 (HDAC6) 抑制剂是针对血液恶性瘤的新兴表观遗传疗法.
非常晚的抗原4 (VLA-4) 在ALL中调解细胞粘附驱动的耐药性 (CAMDR).

研究的目的:

调查选择性HDAC6抑制剂WT161对ALL的治疗潜力.
为了确定WT161是否针对ALL中的VLA-4/焦粘附激酶 (FAK) 信号通路.
在临床前ALL模型中评估WT161单独和与温克里斯结合的疗效.

主要方法:

人类B-ALL和T-ALL细胞系的WT161治疗.
评估增殖,粘附,迁移,细胞亡和细胞循环.
西方斑点用于蛋白质分析,免疫光用于VLA-4表达.
在体内研究中使用与ALL细胞移植的NOD/SCID小鼠.

主要成果:

WT161显著抑制了ALL细胞的增殖,粘附和迁移.
通过降低cAMP水平和抑制蛋白激酶A (PKA) 活性,WT161诱导了亡并抑制了FAK信号通路.
在体内,WT161表现出抗瘤作用,与克里斯结合时增强.

结论:

WT161是一种强大的HDAC6抑制剂,在ALL中具有治疗潜力.
WT161通过抑制PKA活性来破坏VLA-4/FAK通路.
WT161为ALL治疗提供了一个有前途的新疗法策略,特别是在组合疗法中.

关键词:

急性淋巴细胞白血病 (Acute Lymphoblastic Leukemia) 是一种急性淋巴细胞白血病.焦点粘附激酶的焦点粘附激酶这就是PKA PKA.非常晚的抗原-4非常晚.这就是WT1611的特点.

更多相关视频

Assays for Validating Histone Acetyltransferase Inhibitors

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation

Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation

Published on: September 20, 2017

相关概念视频

The JAK-STAT Signaling Pathway

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...